A Randomized, Partially Masked, Controlled, Phase 3 Clinical Study to Evaluate the Efficacy and Safety of RGX-314 Gene Therapy in Participants with nAMD
Clinical Trial Grant
Administered By
Ophthalmology, Vitreoretinal Diseases & Surgery
Awarded By
Regenxbio, Inc.
Start Date
June 3, 2022
End Date
May 31, 2027
Administered By
Ophthalmology, Vitreoretinal Diseases & Surgery
Awarded By
Regenxbio, Inc.
Start Date
June 3, 2022
End Date
May 31, 2027